COG-AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Objective

To compare the progression-free survival (PFS) of a standard chemotherapy approach versus an immunotherapy (IO) approach (brentuximab vedotin and nivolumab) in patients with newly diagnosed early stage classic Hodgkin lymphoma (cHL) who have a rapid early response (RER) as determined by position emission tomography post cycle 2 (PET2) after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy.

National Clinical Trial (NCT) Number: 05675410

National Library of Medicine clinicaltrials.gov Website Address: https://clinicaltrials.gov/study/NCT05675410

Location: Essentia Health Cancer Centers

Research Study Categories

• Pediatric Oncology Studies

Specialties

• Hematology

Contact

Cancer Clinical Trials at 218-786-3308 or 844-681-7944, [email protected]